Lotronex Risk Management Plan Should Not Be Changed Until More Safety Data Is Collected, Cmte. Says

Drug Safety & Risk Management Advisory Committee recommends that RMP should not be altered to increase access to Lotronex. The members suggest GlaxoSmithKline should focus on physician education.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet